10-Q: Xtant Medical Holdings Reports Strong Revenue Growth in Q2 2024, Despite Ongoing Losses

Xtant Medical Holdings saw a significant 48% increase in revenue in the second quarter of 2024 compared to the same period last year, driven by recent acquisitions, but continues to operate at a loss.

Summary

• Xtant Medical Holdings reported a 48% increase in revenue for the three months ended June 30, 2024, reaching $29.9 million, compared to $20.2 million in the same period of 2023.
• The company's revenue for the six months ended June 30, 2024, was $57.8 million, a 51% increase from $38.2 million in the first half of 2023.
• The revenue growth is primarily attributed to the acquisition of Surgalign Holdings' hardware and biologics business.
• Gross profit margin improved to 62.1% for both the three and six months ended June 30, 2024, compared to 61.6% and 60.2% respectively in the same periods of 2023.
• The company experienced a net loss of $3.9 million for the three months ended June 30, 2024, and $8.3 million for the six months ended June 30, 2024.
• Operating expenses increased significantly, with general and administrative expenses up 56% and 58% for the three and six month periods respectively, and sales and marketing expenses up 51% and 63% for the same periods.
• The company's cash and cash equivalents stood at $5.5 million as of June 30, 2024.
• Xtant believes its current cash, recent private placement proceeds, anticipated operating cash flows, and available credit will be sufficient to meet cash requirements through at least August 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth and improved gross margins, the company is still operating at a loss and has identified material weaknesses in internal controls. The need for additional capital raises concerns, resulting in a neutral sentiment.

Positives

• The company experienced substantial revenue growth, driven by recent acquisitions.
• Gross profit margins improved, indicating better operational efficiency.
• Xtant has secured additional financing through a private placement, strengthening its financial position.
• The company believes it has sufficient liquidity to meet its cash requirements through at least August 2025.

Negatives

• The company continues to operate at a net loss, despite revenue growth.
• Operating expenses have increased significantly, offsetting some of the revenue gains.
• The company identified material weaknesses in its internal control over financial reporting.
• The company's disclosure controls and procedures were deemed not effective as of June 30, 2024.

Risks

• The company may require additional capital to fund future operations and business strategy prior to August 2025.
• There is no assurance that the company will be able to secure additional funding on acceptable terms.
• The company's ability to raise additional capital may be limited by the need to obtain consent from existing lenders and investors.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial reports.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.
• The company is subject to potential liabilities under government regulations and various claims and legal actions.

Future Outlook

The company believes its current cash, recent private placement proceeds, anticipated operating cash flows, and available credit will be sufficient to meet cash requirements through at least August 2025, but may require additional capital before then.

Management Comments

• The company is focused on four key growth initiatives: introducing new products, expanding the distribution network, penetrating adjacent markets, and leveraging the growth platform with technology and strategic acquisitions.
• The company is restructuring and streamlining its sales organization following the acquisition of Surgalign Holdings' hardware and biologics business.
• The company is working to remediate identified material weaknesses in internal control over financial reporting.

Industry Context

The medical technology industry is competitive, and Xtant's growth strategy involves acquisitions and expansion into new markets. The company's focus on orthobiologics and spinal implants aligns with the demand for minimally invasive surgical solutions. The company's performance is impacted by factors such as hospital staffing shortages, supply chain disruptions, and regulatory approvals.

Comparison to Industry Standards

• Xtant's revenue growth of 48% and 51% for the three and six months ended June 30, 2024, respectively, is significant compared to the industry average, which typically sees single-digit growth.
• Companies like Medtronic and Johnson & Johnson, which are major players in the medical device industry, have much larger revenue bases but typically grow at a slower pace.
• Smaller companies in the orthobiologics and spinal implant space, such as NuVasive and Globus Medical, have shown similar growth rates in certain periods, but Xtant's growth is notable due to its recent acquisitions.
• Xtant's gross profit margin of 62.1% is competitive with industry standards, but its operating expenses are higher, leading to continued net losses.
• The company's ongoing losses are not uncommon for companies in the growth phase, but the need for additional capital raises concerns about long-term sustainability.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time to time.

Related Party Transactions

• The company has an Investor Rights Agreement with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, which are funds affiliated with OrbiMed Advisors LLC, which beneficially owns 56.2% of the company's common stock.

Stakeholder Impact

• Shareholders may be concerned about the ongoing losses and the need for additional capital raises.
• Employees may be affected by the restructuring of the sales organization and the departure of the Chief Commercial Officer.
• Customers and suppliers may be impacted by the company's ability to maintain its operations and meet its obligations.
• Creditors may be concerned about the company's ability to service its debt.

Next Steps

• The company will continue to implement measures to improve internal control over financial reporting.
• The company will focus on integrating recent acquisitions and streamlining its sales organization.
• The company will continue to pursue its four key growth initiatives.
• The company will monitor its cash position and may seek additional financing if needed.

Key Dates

Keywords

revenue growth, orthobiologics, spinal implants, acquisitions, financial results, net loss, gross profit, operating expenses, internal control, material weakness, private placement, credit facility